Cargando…

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants

Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV protease inhibitor, telaprevir. Variant fitness was est...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adiwijaya, Bambang S., Herrmann, Eva, Hare, Brian, Kieffer, Tara, Lin, Chao, Kwong, Ann D., Garg, Varun, Randle, John C. R., Sarrazin, Christoph, Zeuzem, Stefan, Caron, Paul R.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855330/ https://www.ncbi.nlm.nih.gov/pubmed/20419154 http://dx.doi.org/10.1371/journal.pcbi.1000745

Ejemplares similares

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
por: Adiwijaya, Bambang S., et al.
Publicado: (2012)

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy
por: Dietz, Julia, et al.
Publicado: (2016)

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012)

Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors
por: Wiesmann, F., et al.
Publicado: (2014)

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
por: Dietz, Julia, et al.
Publicado: (2015)

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment
por: Sullivan, James C, et al.
Publicado: (2012)

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes
por: Huang, Ching-I, et al.
Publicado: (2018)

PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
por: Rembeck, Karolina, et al.
Publicado: (2012)

Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α(18)
por: Stross, Claudia, et al.
Publicado: (2016)

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
por: Mücke, Marcus M., et al.
Publicado: (2019)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
por: Zhang, Yu, et al.
Publicado: (2016)

Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan
por: Ali, Amjad, et al.
Publicado: (2011)

Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy
por: Hunyady, Béla, et al.
Publicado: (2018)

HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors
por: Cento, Valeria, et al.
Publicado: (2012)

Deconvoluting the Composition of Low-Frequency Hepatitis C Viral Quasispecies: Comparison of Genotypes and NS3 Resistance-Associated Variants between HCV/HIV Coinfected Hemophiliacs and HCV Monoinfected Patients in Japan
por: Ogishi, Masato, et al.
Publicado: (2015)

Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples
por: Zhang, Eileen Z, et al.
Publicado: (2013)

Distribution pattern of HCV genotypes & its association with viral load
por: Chakravarti, Anita, et al.
Publicado: (2011)

Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia
por: Aissa Larousse, Jameleddine, et al.
Publicado: (2015)

Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
por: Jamalidoust, Marzieh, et al.
Publicado: (2017)

NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain
por: Jimenez-Sousa, María Ángeles, et al.
Publicado: (2016)

Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients
por: Grammatikos, Georgios, et al.
Publicado: (2014)

Do rare variant genotypes predict common variant genotypes?
por: Kent, Jack W, et al.
Publicado: (2011)

Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels
por: Grammatikos, Georgios, et al.
Publicado: (2016)

A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers
por: Vermehren, Johannes, et al.
Publicado: (2012)

Distribution of HCV genotypes and HCV RNA viral load in hepatitis infected patients of Kolar region, Karnataka, India
por: Kaur, Devinder, et al.
Publicado: (2022)

Adapted HCV JFH1 variant is capable of accommodating a large foreign gene insert and allows lower level HCV replication and viral production
por: Wang, Qi, et al.
Publicado: (2018)

Expanding epidemic of recently acquired HCV in HIV-coinfected patients over a period of 10 years
por: Graf, Christiana, et al.
Publicado: (2023)

The correlation of HCV RNA and HCV core antigen in different genotypes of HCV
por: Xiang, Yu, et al.
Publicado: (2018)

Occult HCV or delayed viral clearance from lymphocytes of Chronic HCV genotype 3 patients after interferon therapy
por: Muazzam, Ambreen G, et al.
Publicado: (2011)

Association of genotypes with viral load and biochemical markers in HCV-infected Sindhi patients
por: Riaz, Saba, et al.
Publicado: (2016)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples
por: Warkad, Shrikant Dasharath, et al.
Publicado: (2018)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
por: Garbuglia, Anna Rosa, et al.
Publicado: (2014)

Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability
por: Dultz, Georg, et al.
Publicado: (2021)

A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection
por: Kishida, Yutaka, et al.
Publicado: (2016)

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease
por: Khan, Mahim, et al.
Publicado: (2022)

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
por: Welsch, Christoph, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_5poe5nguj4spa330ae2edoske9